Diffuse midline gliomas are among the most aggressive brain tumors with unfavourable prognosis and poor response towards standard therapy. As diffuse midline gliomas can in principle be recognized and combated by the human immune system, deciphering the specific immune cell receptors might enable to manufacture engineered T cells which can then be transferred to patients with diffuse midline gliomas. The aim of this project is to develop such an adoptive T-cell therapy for patients with diffuse midline gliomas.

Further information here.